Skip to main content
QMSQMS
QMS
  • Welcome to your QMS
  • Quality Manual
  • Procedures
  • Records
  • Legit.Health Plus Version 1.1.0.0
  • Legit.Health Plus Version 1.1.0.1
  • Legit.Health version 2.1 (Legacy MDD)
  • Legit.Health US Version 1.1.0.0
  • Legit.Health Utilities
  • Licenses and accreditations
  • Applicable Standards and Regulations
  • BSI Non-Conformities
    • Technical Review
    • Clinical Review
      • Round 1
        • Item 0: Background & Action Plan
        • Item 1: CER Update Frequency
        • Item 2: Device Description & Claims
        • Item 3: Clinical Data
        • Item 4: Usability
        • Item 5: PMS Plan
        • Item 6: PMCF Plan
        • Item 7: Risk
        • completed-tasks
          • task-3b10-legacy-pms-document-hierarchy-refactor
          • task-3b11-sme-coverage-subspecialty-documentation
          • task-3b12-phase-1-exploratory-per-bucket-c-feature
          • task-3b13-man-2025-cep-cip-completeness
          • task-3b14-ifu-integration-requirements-verification
          • task-3b4-mrmc-dark-phototypes
          • task-3b6-surrogate-endpoint-literature-review
            • Appraisal log — CRIT1–7 rolling table
            • Do we need this task?
            • Integration map — propagation of the surrogate-endpoint validity review
            • references
              • diagnostic-accuracy
              • referral-optimisation
                • Armstrong 2018 — Online vs in-person care for psoriasis: equivalency RCT
                • Chuchu 2018 — Cochrane review: teledermatology for diagnosing skin cancer in adults
                • Eminović 2009 — Cluster RCT: teledermatology reduces dermatology referrals
                • Finnane 2017 — Teledermatology for the diagnosis and management of skin cancer: systematic review
                • Giavina-Bianchi 2020 — Teledermatology reduces referrals and waiting times (São Paulo, 30,976 patients)
                • Jain 2021 — AI tool for skin-condition diagnosis by PCPs and NPs in teledermatology
                • Moreno-Ramirez 2007 — Store-and-forward teledermatology in skin-cancer triage (Seville, 2,009 teleconsultations)
                • Snoswell 2016 — Cost-effectiveness of store-and-forward teledermatology: systematic review
                • Whited 2013 — Clinical-course outcomes: store-and-forward teledermatology vs. conventional consultation RCT
              • severity-assessment
            • Research prompts — external deep-research tools
            • Surrogate-Endpoint Validity in Dermatology AI — Structured Literature Review
          • task-3b7-icd-per-epidemiological-group-vv
          • task-3b8-safety-confirmation-column-definition
          • task-3b9-legacy-pms-conclusions-into-plus-pms-plan
        • Coverage matrix
        • resources
        • Task 3b-5: Autoimmune and Genodermatoses Triangulated-Evidence Package
      • Evidence rank & phases
      • Pre-submission review of R-TF-015-001 CEP and R-TF-015-003 CER
  • Pricing
  • Public tenders
  • Trainings
  • BSI Non-Conformities
  • Clinical Review
  • Round 1
  • completed-tasks
  • task-3b6-surrogate-endpoint-literature-review
  • references
  • referral-optimisation
  • Eminović 2009 — Cluster RCT: teledermatology reduces dermatology referrals

Eminović 2009 — Cluster RCT: teledermatology reduces dermatology referrals

Citation​

Eminović N, de Keizer NF, Wyatt JC, ter Riet G, Peek N, van Weert HC, et al. Teledermatologic consultation and reduction in referrals to dermatologists: a cluster randomized controlled trial. Arch Dermatol. 2009 May;145(5):558–564. DOI: 10.1001/archdermatol.2009.44. PMID 19451500.

Study design and population​

Multicentre cluster RCT, 2 Dutch regions. 85 GPs from 35 practices randomised to teledermatology triage vs. usual referral. 5 dermatologists; 631 patients (327 intervention, 304 control).

Reported metrics​

  • Consultations judged preventable: 39.0 % (teledermatology) vs. 18.3 % (control)
  • Absolute difference 20.7 pp (95 % CI 8.5–32.9)
  • At 1-month dermatologist visit, 20.0 % of teledermatology patients had recovered
  • Patient satisfaction high, no significant difference between arms

Surrogate-to-outcome linkage​

Highest-tier evidence for referral reduction as a care-pathway outcome in a GP-level teledermatology triage context — the exact clinical scenario of a primary-care CDS. Preventable-visit rate is a direct system-level surrogate for specialist-capacity release and reduced wait times.

CRIT1–7 appraisal​

CriterionScoreJustification
CRIT1 Relevance3Direct — GP teledermatology triage with referral-reduction primary outcome.
CRIT2 Methodology3Cluster RCT; pre-specified primary outcome; blinded adjudication.
CRIT3 Reporting3Absolute difference with 95 % CI; patient satisfaction reported.
CRIT4 Applicability3EU primary-care setting, directly applicable.
CRIT5 Evidence weight2Cluster RCT — highest tier available for care-pathway intervention.
CRIT6 Risk of bias2"Preventability" judged retrospectively by dermatologists (not hard endpoint); Dutch referral culture-specific.
CRIT7 Contribution3Core anchor — RCT-level evidence for the referral-reduction surrogate.

Aggregate: very strong.

Limitations and notes​

Pre-dates modern AI triage; retrospective "preventability" judgement; Dutch context.

Strength as anchor​

Very strong. Highest evidence level (cluster RCT) for the referral-appropriateness surrogate in EU primary-care setting. Cited routinely in HTA evaluations (NICE, NIHR, HIQA).

Previous
Chuchu 2018 — Cochrane review: teledermatology for diagnosing skin cancer in adults
Next
Finnane 2017 — Teledermatology for the diagnosis and management of skin cancer: systematic review
  • Citation
  • Study design and population
  • Reported metrics
  • Surrogate-to-outcome linkage
  • CRIT1–7 appraisal
  • Limitations and notes
  • Strength as anchor
All the information contained in this QMS is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI Labs Group S.L.)